Thursday, September 28, 2023
9:39 AM EST – Antibe Therapeutics Inc. : Announced Health Canada’s approval to initiate the pharmacokinetic/pharmacodynamic study of otenaproxesul’s faster-absorbing formulation for acute pain. Set to commence in October, the purpose of the study is to inform the doses for the Phase II trial. Antibe Therapeutics Inc. (T.ATE) shares were unchanged at 0.465.
Stocks in Play: Antibe Therapeutics Inc., Thu, 28 Sep 2023 09:42:06 EST